ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF

A method of treating a cMET-positive solid tumor cancer having low or intermediate expression of cMET, comprising administering an effective amount of an anti-cMET antibody drug conjugate (ADC) to a human subject previously identified or selected as having said cancer, over a sufficient period of time to provide a therapeutic benefit, wherein the antibody component of the ADC exhibits cMET-specific pH-dependent binding, and optionally wherein the antibody comprises heavy and light chain CDRs present in the amino acid sequences as set forth in one of the following pairs:

• SEQ ID NOs:
• 15 & 16;
• SEQ ID NOs:
• 5 & 6;
• SEQ ID NOs:
• 7 & 8;
• SEQ ID NOs:
• 9 & 10;
• SEQ ID NOs:
• 11 & 12;
• SEQ ID NOs:
• 13 & 14;
• SEQ ID NOs:
• 17 & 18;
• SEQ ID NOs:
• 19 & 20;
• SEQ ID NOs:
• 21 & 22;
• SEQ ID NOs:
• 23 & 24;
• SEQ ID NOs:
• 25 & 26;
• SEQ ID NOs:
• 27 & 28;
• SEQ ID NOs:
• 29 & 30;
• SEQ ID NOs:
• 31 & 32;
• and SEQ ID NOs:
• 33 & 34;
• optionally wherein the CDRs are determined using the Kabat or the IMGT system.

A method of treating a cMET-positive solid tumor cancer having a cMET immunohistochemistry score of 1+, 2+, or 3+, and/or an H-score of at least about 50 to 300, comprising administering an effective amount of an anti-cMET antibody drug conjugate (ADC) to a human subject previously identified or selected as having said cancer, over a sufficient period of time to provide a therapeutic benefit, wherein the antibody component of the ADC exhibits cMET-specific pH-dependent binding, wherein the antibody comprises heavy and light chain CDRs present in the amino acid sequences as set forth in one of the following pairs:

• SEQ ID NOs:
• 15 & 16;
• SEQ ID NOs:
• 5 & 6;
• SEQ ID NOs:
• 7 & 8;
• SEQ ID NOs:
• 9 & 10;
• SEQ ID NOs:
• 11 & 12;
• SEQ ID NOs:
• 13 & 14;
• SEQ ID NOs:
• 17 & 18;
• SEQ ID NOs:
• 19 & 20;
• SEQ ID NOs:
• 21 & 22;
• SEQ ID NOs:
• 23 & 24;
• SEQ ID NOs:
• 25 & 26;
• SEQ ID NOs:
• 27 & 28;
• SEQ ID NOs:
• 29 & 30;
• SEQ ID NOs:
• 31 & 32;
• and SEQ ID NOs:
• 33 & 34;
• optionally wherein the CDRs are determined using the Kabat or the IMGT system.

A method of treating a non-squamous non-small cell lung cancer (“nsNSCLC”) tumor that expresses or overexpress c-Met, comprising administering to a human subject having said NSCLC tumor an effective amount of a pharmaceutical composition comprising MYTX-011 and a pharmaceutically acceptable carrier, wherein ≥25% of neoplastic cells from tumor tissue of the c-Met expressing or overexpressing nsNSCLC from the subject have 2+ membrane or membrane plus cytoplasmic staining when assessed by c-Met immunohistochemistry (IHC);

• optionally wherein the composition remains effective for treating cancer when frozen and rethawed up to at least 2 times;
• and
• optionally wherein the carrier comprises L-Histidine;
• L-Histidine HCl, monohydrate;
• D (+)-Trehalose dihydrate;
• and Polysorbate 80.